Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial

Journal of Diabetes and its Complications

Volumn 30, Issue 2, 2016, Pages 350-356

  Ziegler, Dan ^a,b   Low, Phillip A ^c   Freeman, Roy ^d   Tritschler, Hans ^e   Vinik, Aaron I ^f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Orthopedic Surgery   (Germany)

^c MAYO CLINIC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MEDA Pharma GmbH and Co KG   (Germany)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Autonomic function; Cardiovascular risk factors; Diabetic polyneuropathy; Neuropathic impairments; lipoic acid

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; THIOCTIC ACID; ANTIOXIDANT;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART RATE; HUMAN; HYPERPNEA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STAGING; SYSTOLIC BLOOD PRESSURE; TABLET; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FOLLOW UP; PATHOLOGY; PROGNOSIS; REMISSION;

ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; THIOCTIC ACID; TREATMENT OUTCOME;

EID: 84973092407     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.10.018     Document Type: Article

References (40)

1. M.K. Ali, K.M. Bullard, E.W. Gregg, and C. Del Rio A cascade of care for diabetes in the United States: Visualizing the gaps Annals of Internal Medicine 161 2014 681 689
2. American Diabetes Association 6. Glycemic targets Diabetes Care 38 Suppl. 1 2015 S33 S40
3. V.G. Athyros, T.P. Didangelos, D.T. Karamitsos, A.A. Papageorgiou, H. Boudoulas, and A.G. Kontopoulos Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy Acta Cardiologica 53 1998 201 209
4. R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, S. Lafont, C. Bergeonneau, and B. Kassaï C. Cornu Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials BMJ 343 2011 d4169 10.1136/bmj.d4169
5. J.R. Brownrigg, S. de Lusignan, A. McGovern, C. Hughes, M.M. Thompson, K.K. Ray, and R.J. Hinchliffe Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus Heart 100 2014 1837 1843
6. J. Calles-Escandón, L.C. Lovato, D.G. Simons-Morton, D.M. Kendall, R. Pop-Busui, and R.M. Cohen B. Hamilton Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Diabetes Care 33 2010 721 727
7. C.R. Cardoso, and G.F. Salles Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients Journal of Diabetes and its Complications 22 2008 164 170
8. M. Charles, N. Ejskjaer, D.R. Witte, K. Borch-Johnsen, T. Lauritzen, and A. Sandbaek Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: The ADDITION-Denmark study Diabetes Care 34 2011 2244 2249
9. M. Charles, J. Fleischer, D.R. Witte, N. Ejskjaer, K. Borch-Johnsen, T. Lauritzen, and A. Sandbaek Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study Diabetologia 56 2013 101 108
10. D.V. Coppini, P.A. Bowtell, C. Weng, P.J. Young, and P.H. Sönksen Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model Journal of Clinical Epidemiology 53 2000 519-233
11. R.H. Dworkin, D.C. Turk, S. Peirce-Sandner, H. He, M.P. McDermott, and J.T. Farrar M.C. Rowbotham Assay sensitivity and study features in neuropathic pain trials: An ACTTION meta-analysis Neurology 81 2013 67 75
12. P.J. Dyck, J.L. Davies, W.J. Litchy, and P.C. O'Brien Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort Neurology 49 1997 229 239
13. P.J. Dyck, J.E. Norell, H. Tritschler, K. Schuette, R. Samigullin, and D. Ziegler P.C. O'Brien Challenges in design of multicenter trials: End points assessed longitudinally for change and monotonicity Diabetes Care 30 2007 2619 2625
14. K.Y. Forrest, R.E. Maser, G. Pambianco, D.J. Becker, and T.J. Orchard Hypertension as a risk factor for diabetic neuropathy: A prospective study Diabetes 46 1997 665 670
15. C.S. Fox, S.H. Golden, C. Anderson, G.A. Bray, L.E. Burke, I.H. de Boer D.K. Vafiadis American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 38 2015 1777 1803
16. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes New England Journal of Medicine 358 2008 580 591
17. S.S. Kim, J.C. Won, H.S. Kwon, C.H. Kim, J.H. Lee, and T.S. Park B.Y. Cha Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: Results from a nationwide hospital-based study of diabetic neuropathy in Korea Diabetes Research and Clinical Practice 103 2014 522 529
18. R.A. Malik, S. Williamson, C. Abbott, A.L. Carrington, J. Iqbal, W. Schady, and A.J. Boulton Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised double-blind controlled trial Lancet 352 1998 1978 1981
19. C.L. Martin, J.W. Albers, R. Pop-Busui, and DCCT/EDIC Research Group Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study Diabetes Care 37 2014 31 38
20. T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, and Y. Kaneda M. Brownlee Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
21. N. Papanas, and D. Ziegler Efficacy of α-lipoic acid in diabetic neuropathy Expert Opinion on Pharmacotherapy 15 2014 2721 2731
22. Peripheral Nerve Society Diabetic polyneuropathy in controlled clinical trials: Consensus report of the peripheral nerve society Annals of Neurology 38 1995 478 482
23. K. Rajamani, P.G. Colman, L.P. Li, J.D. Best, M. Voysey, M.C. D'Emden A.C. Keech FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial Lancet 373 9677 2009 1780 1788
24. P. Ruggenenti, G. Lauria, I.P. Iliev, A. Fassi, A.P. Ilieva, S. Rota G. Remuzzi DEMAND Study Investigators Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: The delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial Hypertension 58 2011 776 783
25. A. Sandbæk, S.J. Griffin, S.J. Sharp, R.K. Simmons, K. Borch-Johnsen, and G.E. Rutten K. Khunti Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: A randomized controlled trial: The ADDITION-Europe Study Diabetes Care 37 2014 2015 2023
26. M.L. Sands, S.M. Shetterly, G.M. Franklin, and R.F. Hamman Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study Diabetes Care 20 1997 322 329
27. S. Sola, M.Q. Mir, F.A. Cheema, N. Khan-Merchant, R.G. Menon, S. Parthasarathy, and B.V. Khan Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the irbesartan and lipoic acid in endothelial dysfunction (ISLAND) study Circulation 111 2005 343 348
28. S. Tesfaye, N. Chaturvedi, S.E. Eaton, J.D. Ward, C. Manes, C. Ionescu-Tirgoviste J.H. Fuller EURODIAB Prospective Complications Study Group Vascular risk factors and diabetic neuropathy New England Journal of Medicine 352 2005 341 350
29. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus New England Journal of Medicine 329 1993 977 986
30. T.D. Wiggin, K.A. Sullivan, R. Pop-Busui, A. Amato, A.A. Sima, and E.L. Feldman Elevated triglycerides correlate with progression of diabetic neuropathy Diabetes 58 2009 1634 1640
31. K.R. Ylitalo, M. Sowers, and S. Heeringa Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity: National health and nutrition examination survey 2001-2004 Diabetes Care 34 2011 1642 1647
32. L.H. Young, F.J. Wackers, D.A. Chyun, J.A. Davey, E.J. Barrett, R. Taillefer S.E. Inzucchi DIAD Investigators Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial JAMA 301 2009 1547 1555
33. D. Ziegler, S. Buchholz, C. Sohr, J. Nourooz-Zadeh, and M. Roden Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients Acta Diabetologica 52 2015 65 72
34. D. Ziegler, P.A. Low, W.J. Litchy, A.J. Boulton, A.I. Vinik, and R. Freeman P.J. Dyck Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: The NATHAN 1 Trial Diabetes Care 34 2011 2054 2060
35. D. Ziegler, N. Papanas, A.I. Vinik, and J.E. Shaw Epidemiology of polyneuropathy in diabetes and prediabetes Handbook of Clinical Neurology 126 2014 3 22
36. D. Ziegler, W. Rathmann, T. Dickhaus, C. Meisinger, A. Mielck, and KORA Study Group Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: The MONICA/KORA Augsburg Surveys S2 and S3 Diabetes Care 31 2008 464 469
37. D. Ziegler, W. Rathmann, C. Meisinger, T. Dickhaus, A. Mielck, and KORA Study Group Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry European Journal of Pain 13 2009 582 587
38. D. Ziegler, H. Schatz, F. Conrad, F.A. Gries, H. Ulrich, and G. Reichel Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study) Diabetes Care 20 1997 369 373
39. D. Ziegler, E. Schneider, F.G. Boess, L. Berggren, and F. Birklein Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice Journal of Diabetes and its Complications 28 2014 698 704
40. D. Ziegler, A. Voss, W. Rathmann, A. Strom, S. Perz, M. Roden C. Meisinger KORA Study Group Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: The KORA S4 survey Diabetologia 58 2015 1118 1128